再生元制药
REGN
790.74
-5.60
-0.70%
再生元制药
US · REGN
#285 按市值排名
上市于 1970
790.74
-5.60
-0.70%
实时 - 追踪5344个代码 - 心跳于293秒前
· 2026-10-16 20:02
关于 Regeneron Pharmaceuticals
Regeneron 制药, Inc. is a biotechnology company, which 从事 the discovery, invention, 开发, manufacture, and commercialization of medicines. Its product portfolio 包括 the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug 开发 process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was 成立 by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is 总部位于 in Tarrytown, NY.
- 成立时间
- 1988
- 首席执行官
- Dr. Leonard S. Schleifer,M.D.,PhD
- 员工人数
- 15,410
- 总部地址
- Tarrytown, New York, United States of America
- 财年结束日
- 12-31
- 官方网站
- regeneron.com
公司概况
- 交易所
- US
- 股票代码
- REGN
- 市值排名
- #285
- 上市日期
- 1970-01-01
- 市值
- 81.41B
- 流通市值
- 78.24B
- 总股数
- 102.95M
- 流通股数
- 98.95M
行业与主题板块
报价时间 2026-10-16 20:02:12 · 仅供参考，不构成投资建议，也未考虑您的具体情况。
再生元制药 讨论区 0 条评论